Pro Medicus (ASX:PME): FY26 Imaging Contracts and Profit Measures Explained

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Pro Medicus (ASX:PME): FY26 Imaging Contracts and Profit Measures Explained

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Pro Medicus (ASX:PME) reported AUD 261.7 million FY26 revenue.
Underlying EBIT rose 24.4% to AUD 196.1 million.
Ten new contracts carried a combined minimum value of AUD 407 million.
The group reported AUD 252.3 million in cash and other financial assets.

Pro Medicus Limited (ASX:PME) provides medical imaging software and technology used by healthcare organisations to manage, view and interpret diagnostic images. On 12 November 2026, its shares changed hands at AUD 203.37, down 1.90% during the session. The company’s August full-year results set out expanding software revenues, new contract awards and product development in digital pathology and reporting systems. Those developments require separate consideration from the day’s share-price change.

Medical Imaging Software and Customer Deployments

Pro Medicus (ASX:PME) develops healthcare information technology, including the Visage imaging platform, for customers such as hospitals and radiology providers. Its software supports the viewing and workflow of medical images and related information, with implementations taking place through contracts with healthcare institutions. Commercial outcomes depend on signed terms, deployment milestones and customers’ operational requirements. A large stated contract value is not the same thing as Revenue recognised in a particular reporting year. Software installations and clinical workflows can require testing, Training and integration before a contracted platform is used throughout a customer organisation.

FY26 Revenue and Distinct Profit Measures

For FY26, Pro Medicus reported revenue of AUD 261.7 million, up 22.9%. Underlying Earnings before interest and tax reached AUD 196.1 million, an increase of 24.4%, and underlying net profit after tax was AUD 144.7 million, also up 24.1%. Statutory net profit after tax was AUD 265.3 million, up 130.3%. Because the statutory and Underlying Profit figures differ substantially, their presentation should not be interchangeable. Both are company-reported measures but reflect different treatments of items within the accounts. Pro Medicus (ASX:PME) recorded an underlying EBIT Margin of 74.9%, an improvement of 90 basis points.

Contracts, Renewals and Product Development

During FY26, Pro Medicus (ASX:PME) signed ten new contracts with a combined minimum stated value of AUD 407 million. It also renewed six of six contracts, with renewal values totalling AUD 141 million over five-year terms. These amounts reflect contractual commitments over their respective terms and should not be read as cash immediately collected. The company reported launches involving digital pathology and AI-optimised reporting. It also said the Trinity implementation was largely complete and was positioned for a full-year contribution in FY27. Actual contribution remains subject to future reporting rather than being assumed from contract announcements.

Cash Position and Execution Risks

The company reported AUD 252.3 million in cash and other financial assets, and described itself as debt-free in its FY26 release. Pro Medicus (ASX:PME) therefore has a funding position separate from its awarded contract pipeline. Operational risks include implementation timing, cybersecurity, customer concentration, competition, software uptime and the medical regulatory environment. Changes in recognition schedules can affect the period in which a contract contributes revenue. Its international exposure also makes foreign exchange important: the company separately reported constant-currency underlying revenue of AUD 273.5 million, up 28.4%.

What to Watch Next

Later releases may clarify the revenue contribution of newly signed contracts, implementation progress and the uptake of digital pathology and AI-optimised reporting. Investors can also monitor renewals, cash generation and the difference between reported and constant-currency performance. Pro Medicus (ASX:PME) reported an underlying constant-currency EBIT measure of AUD 206 million for FY26, up 30.6%; changes in currency can therefore affect comparisons with reported results. Continued contract execution, rather than headline award totals alone, will help explain future operating results.

Key Insights

Pro Medicus (ASX:PME) reported growth in FY26 revenue and underlying earnings, announced new imaging contracts and maintained a debt-free position. Implementation milestones, contract conversion into recognised revenue and the distinction between statutory and underlying profit are central to interpreting its subsequent performance.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.